Recruitment of inflammatory cells to tumor has been well documented, with the most frequent inhabitants being macrophages termed as tumor associated macrophages, (TAMs). Their presence was thought to be an evidence of immune system initiating a fight response towards the tumor, i.e. immune surveillance. This is the case too initially, when TAMs majorly exhibit an M1 phenotype, but their continued presence in tumor microenvironment brings about their polarization to M2 phenotype, which not only participate in continued sustenance of existing tumor but also open up deleterious avenues for further progression and metastasis of cancer. Current perspective is built around this very premise and focuses specifically on TAMs and how they are being targeted by researchers working in annals of nanomedicine. To do so, we dwell into tumor microenvironment and focus on nanotechnology based drug delivery aspects which have either been already or can be potentially employed in the future to target tumor associated macrophages for improved immunoadjuvant therapy of cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2017.03.395DOI Listing

Publication Analysis

Top Keywords

tumor associated
12
associated macrophages
12
macrophages tams
8
tumor microenvironment
8
tumor
7
targeting tumor
4
macrophages
4
tams
4
tams nanocarriers
4
nanocarriers recruitment
4

Similar Publications

Short-term starvation boosts anti-PD-L1 therapy by reshaping tumor-associated macrophages in hepatocellular carcinoma.

Hepatology

January 2025

Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, People's Republic of China.

Background And Aims: Immune checkpoint inhibitors (ICIs) have revolutionized systemic hepatocellular carcinoma (HCC) treatment. Nevertheless, numerous patients are refractory to ICIs therapy. It is currently unknown whether diet therapies such as short-term starvation (STS) combined with ICIs can be used to treat HCC.

View Article and Find Full Text PDF

Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography.

Eur J Nucl Med Mol Imaging

January 2025

Institute of Radiation Medicine, Fudan University, Xietu Road 2094, Shanghai, 200032, China.

Objectives: Mesothelin (MSLN) is an antigen that is overexpressed in various cancers, and its interaction with tumor-associated cancer antigen 125 plays a multifaceted role in tumor metastasis. The serum MSLN expression level can be detected using enzyme-linked immunosorbent assay; however, non-invasive visualization of its expression at the tumor site is currently lacking. Therefore, the aim of this study was to develop a molecular probe for imaging MSLN expression through positron emission tomography (PET).

View Article and Find Full Text PDF

Unlocking the potential of : A breakthrough in liver cancer treatment Wnt/β-catenin pathway modulation.

World J Gastroenterol

January 2025

Department of Internal Medicine, Mixed Hospital of Laghouat, Laghouat Faculty of Medicine, Amar Telidji University, Laghouat 03000, Algeria.

Liver cancer remains a significant global health challenge, characterized by high incidence and mortality rates. Despite advancements in medical treatments, the prognosis for liver cancer patients remains poor, highlighting the urgent need for novel therapeutic approaches. Traditional Chinese medicine (TCM), particularly (CB), has shown promise in addressing this need due to its multi-target therapeutic mechanisms.

View Article and Find Full Text PDF
Article Synopsis
  • Colorectal cancer (CRC) is a major cause of cancer deaths, and oxaliplatin (OXA) is a primary treatment that faces challenges due to the tumor microenvironment (TME).
  • A new multifunctional nanosystem, Rg3-Lip-OXA/CaO, uses Ginsenoside Rg3 liposomes to target CRC cells, delivering OXA and calcium peroxide (CaO) together.
  • Research showed that this nanosystem had good stability and release properties, effectively targeted cancer cells, and significantly suppressed tumor growth in mice, while also showing manageable acute toxicity.
View Article and Find Full Text PDF

Background: Neoadjuvant, endocrine, and targeted therapies have significantly improved the prognosis of breast cancer (BC). However, due to the high heterogeneity of cancer, some patients cannot benefit from existing treatments. Increasing evidence suggests that amino acids and their metabolites can alter the tumor malignant behavior through reshaping tumor microenvironment and regulation of immune cell function.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!